UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 271

Sortiert nach

Triple-negative breast cancer—current status and future directions

Annals of oncology, 2009-12, Vol.20 (12), p.1913-1927

2009

Volltextzugriff (PDF)

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of oncology, 2017-11, Vol.28 (11), p.2768-2772

2017

Volltextzugriff (PDF)

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2014-08, Vol.25 (8), p.1551-1557

2014

Volltextzugriff (PDF)

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Annals of oncology, 2023-06, Vol.34 (6), p.531-542

2023

Volltextzugriff (PDF)

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Annals of oncology, 2008-05, Vol.19 (5), p.861-870

2008

Volltextzugriff (PDF)

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

Annals of oncology, 2015-04, Vol.26 (4), p.688-695

2015

Volltextzugriff (PDF)

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Annals of oncology, 2019-05, Vol.30, p.iii67-iii67

2019

Volltextzugriff (PDF)

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii703-viii703

2018

Volltextzugriff (PDF)

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Annals of oncology, 2016-06, Vol.27 (6), p.1035-1040

2016

Volltextzugriff (PDF)

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2017-11, Vol.28 (11), p.2899-2899

2017

Volltextzugriff (PDF)

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

Annals of oncology, 2015-10, Vol.26 (10), p.2198-2199

2015

Volltextzugriff (PDF)

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression"

Annals of oncology, 2017-11, Vol.28 (11), p.2899

2017

Volltextzugriff (PDF)

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Annals of oncology, 2014-01, Vol.25 (1), p.75-80

2014

Volltextzugriff (PDF)

Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes

Breast (Edinburgh), 2017-03, Vol.32, p.S93-S93

2017

Volltextzugriff (PDF)

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

Breast (Edinburgh), 2017-03, Vol.32, p.S98-S98

2017

Volltextzugriff (PDF)

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

European journal of cancer (1990), 2015-09, Vol.51, p.S311-S311

2015

Volltextzugriff (PDF)

Klinische Pathologie des Mammakarzinoms

Gynäkologie (Heidelberg, Germany), 2016-10, Vol.49 (10), p.737-745

2016

Volltextzugriff (PDF)

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study

Breast (Edinburgh), 2015-03, Vol.24, p.S104-S105

2015

Volltextzugriff (PDF)

P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial

Breast (Edinburgh), 2015-03, Vol.24, p.S110-S110

2015

Volltextzugriff (PDF)

260 Primary Tumor in Breast Cancer and Its Phenotype in Positive Lymph Nodes and Later Disease Recurrence (metastatic Breast Cancer): Results of the PRIMET-trial (WSG/DETECT)

European journal of cancer (1990), 2012-03, Vol.48, p.S118-S118

2012

Volltextzugriff (PDF)

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

European journal of nuclear medicine and molecular imaging, 1999-03, Vol.26 (3), p.226-230

1999

Volltextzugriff (PDF)

PP 30 Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis)

European journal of cancer (1990), 2011, Vol.47, p.S33-S34

2011

Volltextzugriff (PDF)

The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual

European journal of cancer (1990), 2011, Vol.47, p.7-7

2011

Volltextzugriff (PDF)

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

The New England journal of medicine, 2005-10, Vol.353 (16), p.1659-1672

2005

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(229)
Mit Volltextzugriff
(243)

Publikationsform

Sprache

Englisch
(219)
Deutsch
(53)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Humans
(51)
Physics
(48)
Physical Sciences
(42)
Female
(41)
Astrophysics
(39)
Life Sciences & Biomedicine
(39)
Sciences Of The Universe
(32)
Astronomy & Astrophysics
(31)
High Energy Astrophysical Phenomena
(29)
Physics, Particles & Fields
(26)
Middle Aged
(24)
Biological And Medical Sciences
(22)
Augers
(21)
Breast Neoplasms - Drug Therapy
(21)
Oncology
(21)
Medical Sciences
(20)
Adult
(19)
Breast Cancer
(17)
Cosmic Rays
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Triple-negative breast cancer—current status and future directions

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression"

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

Klinische Pathologie des Mammakarzinoms

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study

P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial

260 Primary Tumor in Breast Cancer and Its Phenotype in Positive Lymph Nodes and Later Disease Recurrence (metastatic Breast Cancer): Results of the PRIMET-trial (WSG/DETECT)

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

PP 30 Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis)

The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Suchergebnisse filtern